Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
1.340
-0.060 (-4.29%)
At close: Apr 24, 2026, 4:00 PM EDT
1.330
-0.010 (-0.75%)
After-hours: Apr 24, 2026, 7:30 PM EDT
Allarity Therapeutics Revenue
In the year 2025, Allarity Therapeutics had annual revenue of $320.00K. Allarity Therapeutics had revenue of $320.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$320.00K
Revenue Growth
n/a
P/S Ratio
66.24
Revenue / Employee
$40,000
Employees
8
Market Cap
21.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 320.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Marker Therapeutics | 3.55M |
| OSR Holdings | 2.91M |
| Vistagen Therapeutics | 789.00K |
| VYNE Therapeutics | 570.00K |
| Exicure | 500.00K |
| Lexaria Bioscience | 368.00K |
ALLR News
- 26 days ago - Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress - GlobeNewsWire
- 7 weeks ago - Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need - GlobeNewsWire
- 2 months ago - Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment - GlobeNewsWire
- 4 months ago - Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders - GlobeNewsWire
- 5 months ago - Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 months ago - Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months - GlobeNewsWire
- 7 months ago - Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025 - GlobeNewsWire